OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as TRANCE, RANKL and ODF) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit defects in early differentiation of T and B lymphocytes. Surprisingly, opgl-deficient mice lack all lymph nodes but have normal splenic structure and Peyer's patches. Thus OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and is an essential osteoclast differentiation factor in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor B ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“In the absence of RANK or RANKL, osteoclasts cannot form, function, or survive (62-64, 110, 111).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“RANK and RANKL knockout mice were virtual phenocopies of each other (62)(63)(64), which indicated that RANK and RANKL had few if any roles beyond their mutual interactions.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Another unexpected phenotype found in RANK and RANKL knockout mice was the total lack of lymph nodes (62,64).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Examination of mice genetically deficient in RANKL, RANK, or OPG also revealed no overt dendritic cell defects (62,64,170).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P., Montgomery, C., Geske, R., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 2,016
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Self-citationManolagas, S. C., & Jilka, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320506 · Cited by 1,668
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.
Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., Maraskovsky, E., Gliniak, B. C., Park, L. S., Ziegler, S. F., Williams, D. E., Ware, C. B., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.5.1955 · Cited by 1,555
c-Fos: a Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone Remodeling
Grigoriadis, A. E., Wang, Z.-Q., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., & Wagner, E. F. (1994) · Science · doi:10.1126/science.7939685 · Cited by 1,260
Cited by
Items 101–200 of 1,030
The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond
Dostert, C., Grusdat, M., Letellier, E., & Brenner, D. (2019) · Physiological Reviews · doi:10.1152/physrev.00045.2017 · Cited by 498
“The importance of the OPG/RANKL/RANK triad in bone homeostasis has been dramatically illustrated by the defects observed in RANKL- and RANK-deficient mice, including severe osteopetrosis, defective tooth eruption, and a complete absence of osteoclasts (117, 227, 249).”
BackgroundManolagas, S. C. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.385 · Cited by 517
Browner, W. S., Lui, L.-Y., & Cummings, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7192 · Cited by 506
Compston, J. E. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.419 · Cited by 511
Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., & Choi, Y. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201394498 · Cited by 518
Matsumoto, M., Sudo, T., Saito, T., Osada, H., & Tsujimoto, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001229200 · Cited by 508
Roggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G., & Pacifici, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251534698 · Cited by 513
Tolar, J., Teitelbaum, S. L., & Orchard, P. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040952 · Cited by 506
Jimi, E., Aoki, K., Saito, H., D'Acquisto, F., May, M. J., Nakamura, I., Sudo, T., Kojima, T., Okamoto, F., Fukushima, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1054 · Cited by 501
Microenvironmental niches in the bone marrow required for B-cell development
Nagasawa, T. (2006) · Nature Reviews Immunology · doi:10.1038/nri1780 · Cited by 477
Zhang, Y.-H., Heulsmann, A., Tondravi, M. M., Mukherjee, A., & Abu-Amer, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008198200 · Cited by 498
Akiyama, T., Shimo, Y., Yanai, H., Qin, J., Ohshima, D., Maruyama, Y., Asaumi, Y., Kitazawa, J., Takayanagi, H., Penninger, J. M., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.06.015 · Cited by 503
Self-citationHonore, P., Luger, N. M., Sabino, M. A. C., Schwei, M. J., Rogers, S. D., Mach, D. B., O'keefe, P. F., Ramnaraine, M. L., Clohisy, D. R., & Mantyh, P. W. (2000) · Nature Medicine · doi:10.1038/74999 · Cited by 498
“Osteoclasts are the body's principal bone-resorbing cells, and their formation, survival and bone-resorbing activity can be potently inhibited by the soluble tumor necrosis factor (TNF) receptor family molecule osteoprotegerin (OPG”
BackgroundRossi, S. W., Kim, M.-Y., Leibbrandt, A., Parnell, S. M., Jenkinson, W. E., Glanville, S. H., McConnell, F. M., Scott, H. S., Penninger, J. M., Jenkinson, E. J., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062497 · Cited by 487
“Studies on LTi cells in lymph node development show that interactions between the cell surface receptor RANK and its ligand RANKL (also known as TRANCE) are important (25, 26).”
Self-citationMundy, G. R. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00353.x · Cited by 478
Teng, Y.-T. A., Nguyen, H., Gao, X., Kong, Y.-Y., Gorczynski, R. M., Singh, B., Ellen, R. P., & Penninger, J. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10763 · Cited by 493
“Loss of OPG-L expression in gene-targeted mice results in severe osteopetrosis and a defect in tooth eruption due to a complete loss of osteoclast development (27).”
BackgroundSelf-citationPalmqvist, P., Persson, E., Conaway, H. H., & Lerner, U. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.6.3353 · Cited by 486
Role of EMT in Metastasis and Therapy Resistance
Smith, B., & Bhowmick, N. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5020017 · Cited by 484
“Further profile analysis of bone‐specific proteins osteopontin (OPN), osteocalcin (OC), bone sialoprotein (BSP), and osteoprotegrin (OPG) demonstrated expression in prostate cancer epithelia [95–97].”
BackgroundOsteoimmunology and the effects of the immune system on bone
Takayanagi, H. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.217 · Cited by 487
“RANKL-deficient, but not RANK-deficient, mice had a reduced thymus size, suggesting that RANKL might bind another receptor during thymocyte development”
BackgroundEpithelial M Cells: Differentiation and Function
Kraehenbuhl, J.-P., & Neutra, M. R. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.301 · Cited by 474
Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model
Alexander, K. A., Chang, M. K., Maylin, E. R., Kohler, T., Müller, R., Wu, A. C., Van Rooijen, N., Sweet, M. J., Hume, D. A., Raggatt, L. J., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.354 · Cited by 485
“In addition to CSF-1, the formation of osteoclasts requires signaling from receptor activator of NF-kB ligand (RANKL),((20)) and this signal can be blocked by osteoprotegerin.”
BackgroundThe effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
Self-citationJono, S., Ikari, Y., Shioi, A., Mori, K., Miki, T., Hara, K., & Nishizawa, Y. (2002) · Circulation · doi:10.1161/01.cir.0000031524.49139.29 · Cited by 489
Cao, Y., Bonizzi, G., Seagroves, T. N., Greten, F. R., Johnson, R., Schmidt, E. V., & Karin, M. (2001) · Cell · doi:10.1016/s0092-8674(01)00599-2 · Cited by 482
Developmental origin, functional maintenance and genetic rescue of osteoclasts
Jacome-Galarza, C. E., Percin, G. I., Muller, J. T., Mass, E., Lazarov, T., Eitler, J., Rauner, M., Yadav, V. K., Crozet, L., Bohm, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1105-7 · Cited by 475
Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin
Collin-Osdoby, P. (2004) · Circulation Research · doi:10.1161/01.res.0000149165.99974.12 · Cited by 473
Osteoclasts are essential for TNF-α-mediated joint destruction.
Redlich, K., Hayer, S., Ricci, R., David, J.-P., Tohidast-Akrad, M., Kollias, G., Steiner, G., Smolen, J. S., Wagner, E. F., & Schett, G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215582 · Cited by 474
Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis
Kobayashi, N., Kadono, Y., Naito, A., Matsumoto, K., Yamamoto, T., Tanaka, S., & Inoue, J.-I. (2001) · The EMBO Journal · doi:10.1093/emboj/20.6.1271 · Cited by 466
Ikeda, F., Nishimura, R., Matsubara, T., Tanaka, S., Inoue, J.-I., Reddy, S. V., Hata, K., Yamashita, K., Hiraga, T., Watanabe, T., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419657 · Cited by 417
“A TNF family member, receptor activator of NF-κB ligand (RANKL), which is expressed as a membrane-bound protein in osteoblasts and stromal cells, promotes the differentiation of osteoclast precursor cells into osteoclasts (4, 5).”
Mócsai, A., Humphrey, M. B., Van Ziffle, J. A. G., Hu, Y., Burghardt, A., Spusta, S. C., Majumdar, S., Lanier, L. L., Lowell, C. A., & Nakamura, M. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401602101 · Cited by 463
Tsuji, M., Suzuki, K., Kitamura, H., Maruya, M., Kinoshita, K., Ivanov, I. I., Itoh, K., Littman, D. R., & Fagarasan, S. (2008) · Immunity · doi:10.1016/j.immuni.2008.05.014 · Cited by 441
Bouchon, A., Hernández-Munain, C., Cella, M., & Colonna, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.8.1111 · Cited by 460
Walsh, M. C., Lee, J., & Choi, Y. (2015) · Immunological Reviews · doi:10.1111/imr.12302 · Cited by 438
“lacking either gene exhibit severe osteopetrosis, occluded BM cavities, failure of tooth eruption, and near absence of detectable osteoclasts (153, 154).”
Inoue, J.-I., Ishida, T., Tsukamoto, N., Kobayashi, N., Naito, A., Azuma, S., & Yamamoto, T. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4733 · Cited by 447
The role of NFAT in osteoclast formation
TAKAYANAGI, H. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.071 · Cited by 442
Matsumoto, M., Kogawa, M., Wada, S., Takayanagi, H., Tsujimoto, M., Katayama, S., Hisatake, K., & Nogi, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408795200 · Cited by 436
Hikosaka, Y., Nitta, T., Ohigashi, I., Yano, K., Ishimaru, N., Hayashi, Y., Matsumoto, M., Matsuo, K., Penninger, J. M., Takayanagi, H., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.06.018 · Cited by 433
Self-citationDenosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone
Branstetter, D. G., Nelson, S. D., Manivel, J. C., Blay, J.-Y., Chawla, S., Thomas, D. M., Jun, S., & Jacobs, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0578 · Cited by 426
“bition of normal bone remodeling by interfering with this pathway has been clearly established (40, 41).”
BackgroundMa, Y. L., Cain, R. L., Halladay, D. L., Yang, X., Zeng, Q., Miles, R. R., Chandrasekhar, S., Martin, T. J., & Onyia, J. E. (2001) · Endocrinology · doi:10.1210/endo.142.9.8356 · Cited by 428
Activity loss and the onset of depressive symptoms: Do some activities matter more than others?
Katz, P. P., & Yelin, E. H. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200105)44:5<1194::aid-anr203>3.0.co;2-6 · Cited by 175
RANK/RANKL: Regulators of Immune Responses and Bone Physiology
Leibbrandt, A., & Penninger, J. M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1443.016 · Cited by 420
Self-citationUdagawa, N., Takahashi, N., Jimi, E., Matsuzaki, K., Tsurukai, T., Itoh, K., Nakagawa, N., Yasuda, H., Goto, M., Tsuda, E., et al. (1999) · Bone · doi:10.1016/s8756-3282(99)00210-0 · Cited by 412
Kotake, S., Udagawa, N., Hakoda, M., Mogi, M., Yano, K., Tsuda, E., Takahashi, K., Furuya, T., Ishiyama, S., Kim, K., et al. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200105)44:5<1003::aid-anr179>3.0.co;2-# · Cited by 420
Activated T Lymphocytes Support Osteoclast Formation in Vitro
Horwood, N. J., Kartsogiannis, V., Quinn, J. M. W., Romas, E., Martin, T. J., & Gillespie, M. T. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1623 · Cited by 416
Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., & Barillé, S. (2001) · Blood · doi:10.1182/blood.v98.13.3527 · Cited by 415
Ca 2+ ‐NFATc1 signaling is an essential axis of osteoclast differentiation
Negishi‐Koga, T., & Takayanagi, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00821.x · Cited by 415
“The essential role of RANKL (10, 21) and its receptor RANK (11, 22) was also confirmed by targeted disruption studies.”
BackgroundRomas, E., Gillespie, M. T., & Martin, T. J. (2002) · Bone · doi:10.1016/s8756-3282(01)00682-2 · Cited by 411
Yamashita, T., Yao, Z., Li, F., Zhang, Q., Badell, I. R., Schwarz, E. M., Takeshita, S., Wagner, E. F., Noda, M., Matsuo, K., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610701200 · Cited by 408
Mechanistic insight into osteoclast differentiation in osteoimmunology
Takayanagi, H. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0612-6 · Cited by 413
“Penninger and colleagues [8, 12, 13] contributed to the development of osteoimmunology by generating a series of knockout mice and establishing the role of the RANKL/ RANK system in the pathogenesis of bone diseases and published an extensive review article on the RANKL system [14].”
BackgroundPike, J. W., & Meyer, M. B. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.02.007 · Cited by 394
Udagawa, N., Takahashi, N., Yasuda, H., Mizuno, A., Itoh, K., Ueno, Y., Shinki, T., Gillespie, M. T., Martin, T. J., Higashio, K., et al. (2000) · Endocrinology · doi:10.1210/en.141.9.3478 · Cited by 404
“This is supported by the finding that the targeted disruption of the gene encoding either RANKL (25) or RANK (26, 27) similarly leads to severe osteopetrosis with a complete absence of TRAPpositive cells in the bone tissue in mice.”
BackgroundRANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function
Schoppet, M., Preissner, K. T., & Hofbauer, L. C. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000012303.37971.da · Cited by 405
Lubberts, E., Joosten, L. A. B., Oppers, B., van den Bersselaar, L., Coenen-de Roo, C. J. J., Kolls, J. K., Schwarzenberger, P., van de Loo, F. A. J., & van den Berg, W. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.2.1004 · Cited by 401
“IL-17 induced the expression of receptor activator of NFkB ligand (RANKL), which is a crucial factor in bone resorption (15, 16).”
BackgroundNiches for Hematopoietic Stem Cells and Their Progeny
Wei, Q., & Frenette, P. S. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.024 · Cited by 381
“Improved immunofluorescence analyses of either bisected or sectioned unprocessed bones also showed that endogenous HSCs are located in a perivascular niche that is enriched near the endosteum (Nombela-Arrieta et al., 2013, Takaku et al., 2010, Kubota et al., 2008).”
PTH Differentially Regulates Expression of RANKL and OPG
Huang, J. C., Sakata, T., Pfleger, L. L., Bencsik, M., Halloran, B. P., Bikle, D. D., & Nissenson, R. A. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301226 · Cited by 382
“At specific time-points of cell culture, cells were stimulated with bovine PTH peptide [bPTH (1-34)] for 2 h.”
BackgroundMethodInfluentialEpidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells
Loser, K., Mehling, A., Loeser, S., Apelt, J., Kuhn, A., Grabbe, S., Schwarz, T., Penninger, J. M., & Beissert, S. (2006) · Nature Medicine · doi:10.1038/nm1518 · Cited by 402
“Discussion RANKL and RANK are essential regulators of osteoclast differentiation and control the formation of a lactating mammary gland during pregnanc”
BackgroundSelf-citationCollin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W., & Osdoby, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010153200 · Cited by 398
Pathogenesis of myeloma bone disease
Roodman, G. D. (2009) · Leukemia · doi:10.1038/leu.2008.336 · Cited by 398
Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL
Sobacchi, C., Frattini, A., Guerrini, M. M., Abinun, M., Pangrazio, A., Susani, L., Bredius, R., Mancini, G., Cant, A., Bishop, N., et al. (2007) · Nature Genetics · doi:10.1038/ng2076 · Cited by 389
Recent advances in osteoclast biology
Ono, T., & Nakashima, T. (2018) · Histochemistry and Cell Biology · doi:10.1007/s00418-018-1636-2 · Cited by 384
Delogu, A., Schebesta, A., Sun, Q., Aschenbrenner, K., Perlot, T., & Busslinger, M. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.012 · Cited by 365
The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models.
Lubberts, E., Koenders, M. I., & van den Berg, W. B. (2005) · Arthritis Research · doi:10.1186/ar1478 · Cited by 439
Rheumatic diseases: the effects of inflammation on bone
Walsh, N. C., Crotti, T. N., Goldring, S. R., & Gravallese, E. M. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00338.x · Cited by 380
“(3) demonstrated that activated T cells provide a source of RANKL in the rat antigen-induced”
BackgroundSignal transduction by receptor activator of nuclear factor kappa B in osteoclasts
Lee, Z. H., & Kim, H.-H. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00695-8 · Cited by 381
Luo, X.-H., Guo, L.-J., Xie, H., Yuan, L.-Q., Wu, X.-P., Zhou, H.-D., & Liao, E.-Y. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060707 · Cited by 369
“Injection of exogenous RANKL in mice induces an osteoporotic phenotype, and RANKL knockout mice have severe osteopetrosis,((25)) whereas OPG attaches to RANKL, thereby blocking osteoclastogenesis.”
BackgroundOsteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Croucher, P. I. (2001) · Blood · doi:10.1182/blood.v98.13.3534 · Cited by 377
Bone loss in inflammatory disorders
Hardy, R., & Cooper, M. S. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0568 · Cited by 365
“The importance of OPG and RANKL are highlighted in various mouse models, including mice lacking RANK or RANKL, or overexpressing OPG (Simonet et al. 1997, Dougall et al. 1999, Kong et al. 1999b).”
BackgroundLGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption
Luo, J., Yang, Z., Ma, Y., Yue, Z., Lin, H., Qu, G., Huang, J., Dai, W., Li, C., Zheng, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4076 · Cited by 370
Self-citationOsteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis
Romas, E., Sims, N. A., Hards, D. K., Lindsay, M., Quinn, J. W. M., Ryan, P. F. J., Dunstan, C. R., Martin, T. J., & Gillespie, M. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64417-3 · Cited by 368
“Besides osteoclast differentiation, RANK mediates dendritic cell survival, T- and B-cell development, and lymph node organogenesis.(4,35) It is possible that autoreactive T cell/dendritic cell-to-cell interactions involving RANK are important for initiation and/or perpetuation of inflammatory synovitis.”
BackgroundSelf-citationThe role of the immune system in the pathophysiology of osteoporosis
Clowes, J. A., Riggs, B. L., & Khosla, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00334.x · Cited by 359
“In addition, the OPG knockout mouse has defects in B-lymphocyte and T-lymphocyte maturation, thymic hypoplasia, and LN agenesis (67).”
BackgroundSrivastava, S., Toraldo, G., Weitzmann, M. N., Cenci, S., Ross, F. P., & Pacifici, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010764200 · Cited by 358
New insights into osteoclastogenic signaling mechanisms
Nakashima, T., Hayashi, M., & Takayanagi, H. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.05.005 · Cited by 342
Dejardin, E. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.08.007 · Cited by 344
The RANKL‐OPG system in clinical periodontology
Belibasakis, G. N., & Bostanci, N. (2012) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2011.01810.x · Cited by 352
Buduneli, N., & Kinane, D. F. (2011) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2010.01670.x · Cited by 348
“This ligand can be found as a cell membrane-bound variant (mRANKL) or in a primary soluble (secreted) form, which has been described in activated T cells (Kong et al. 1999).”
C ellular, M olecular, and G enetic D eterminants of T ooth E ruption
Wise, G. E., Frazier-Bowers, S., & D’Souza, R. N. (2002) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130201300403 · Cited by 362
“Recently, it has been shown that knockout mice devoid of the osteoclast differentiation factor (ODF) gene, a gene that is required for osteoclast formation and activation , have unerupted teeth (Kong et al., 1999).”
InfluentialHashizume, M., Hayakawa, N., & Mihara, M. (2008) · Rheumatology · doi:10.1093/rheumatology/ken363 · Cited by 347
Lubberts, E., van den Bersselaar, L., Oppers-Walgreen, B., Schwarzenberger, P., Coenen-de Roo, C. J. J., Kolls, J. K., Joosten, L. A. B., & van den Berg, W. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.5.2655 · Cited by 348
“The balance between RANKL-RANK signaling and the levels of the decoy receptor OPG regulate development and activation of osteoclasts and bone metabolism (15, 16).”
BackgroundNF-κB signaling and bone resorption
Abu-Amer, Y. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2313-x · Cited by 340
“With the discovery of the RANK/RANKL signaling system in the late 1990s [16, 17], the critical pieces of the NF-κB puzzle pertaining to osteoclast differentiation and”
Kaneko, H., Arakawa, T., Mano, H., Kaneda, T., Ogasawara, A., Nakagawa, M., Toyama, Y., Yabe, Y., Kumegawa, M., & Hakeda, Y. (2000) · Bone · doi:10.1016/s8756-3282(00)00358-6 · Cited by 348
Parathyroid hormone-dependent signaling pathways regulating genes in bone cells
Swarthout, J. T., D'Alonzo, R. C., Selvamurugan, N., & Partridge, N. C. (2002) · Gene · doi:10.1016/s0378-1119(01)00798-3 · Cited by 340
Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice
Kaifu, T., Nakahara, J., Inui, M., Mishima, K., Momiyama, T., Kaji, M., Sugahara, A., Koito, H., Ujike-Asai, A., Nakamura, A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16923 · Cited by 343
“Multinucleated, mature osteoclasts with bone-resorption activity can be induced in vitro from bone marrow cells in the presence of M-CSF (26) and RANKL (27).”
InfluentialDevelopment of Secondary Lymphoid Organs
Randall, T. D., Carragher, D. M., & Rangel-Moreno, J. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090257 · Cited by 339
Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation
Matsuo, K., Owens, J. M., Tonko, M., Elliott, C., Chambers, T. J., & Wagner, E. F. (2000) · Nature Genetics · doi:10.1038/72855 · Cited by 341
“These results indicate that the expression of the two components of Ap-1, c-Fos and Fra-1, is regulated by Rank signalling, the key regulator of osteoclastogenesi”
BackgroundThe new bone biology: Pathologic, molecular, and clinical correlates
Cohen Jr., M. M. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31368 · Cited by 335
Roodman, G. D., & Windle, J. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24281 · Cited by 340
Knoop, K. A., Kumar, N., Butler, B. R., Sakthivel, S. K., Taylor, R. T., Nochi, T., Akiba, H., Yagita, H., Kiyono, H., & Williams, I. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901563 · Cited by 323
“RANKL is not required for PP development, but the reduced size of PP reported in two independent lines of RANKL-deficient mice indicates that RANKL contributes to normal PP development (22, 23).”
BackgroundInfluentialGravallese, E. M. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii84 · Cited by 328
Peyer's patches: organizing B‐cell responses at the intestinal frontier
Reboldi, A., & Cyster, J. G. (2016) · Immunological Reviews · doi:10.1111/imr.12400 · Cited by 311
“However, TNFSF11-deficient mice do show a reduced size of PP (18).”
BackgroundOsteoMacs: Key players around bone biomaterials
Miron, R. J., & Bosshardt, D. D. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.017 · Cited by 321
D'Amelio, P., Grimaldi, A., Di Bella, S., Brianza, S. Z. M., Cristofaro, M. A., Tamone, C., Giribaldi, G., Ulliers, D., Pescarmona, G. P., & Isaia, G. (2008) · Bone · doi:10.1016/j.bone.2008.02.017 · Cited by 331
“OC formation occurs when monocytes are co-stimulated by the essential osteoclastogenic factors RANKL and M-CSF [2–4], but additional inflammatory cytokines are responsible for the up-regulation of OC formation observed in estrogen deficiency.”
BackgroundIntrinsic Lymphotoxin-β Receptor Requirement for Homeostasis of Lymphoid Tissue Dendritic Cells
Kabashima, K., Banks, T. A., Ansel, K. M., Lu, T. T., Ware, C. F., & Cyster, J. G. (2005) · Immunity · doi:10.1016/j.immuni.2005.02.007 · Cited by 327
Kartsogiannis, V, Zhou, H., Horwood, N. J., Thomas, R. J., Hards, D. K., Quinn, J. M. W., Niforas, P., Ng, K. W., Martin, T. J., & Gillespie, M. T. (1999) · Bone · doi:10.1016/s8756-3282(99)00214-8 · Cited by 324
Mori, T., Miyamoto, T., Yoshida, H., Asakawa, M., Kawasumi, M., Kobayashi, T., Morioka, H., Chiba, K., Toyama, Y., & Yoshimura, A. (2011) · International Immunology · doi:10.1093/intimm/dxr077 · Cited by 328
Self-citationTanaka, S., Nakamura, K., Takahasi, N., & Suda, T. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00327.x · Cited by 320
Ox40-Ligand Has a Critical Costimulatory Role in Dendritic Cell:T Cell Interactions
Chen, A. I., McAdam, A. J., Buhlmann, J. E., Scott, S., Lupher, M. L., Greenfield, E. A., Baum, P. R., Fanslow, W. C., Calderhead, D. M., Freeman, G. J., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80143-0 · Cited by 321
Animal models for osteoporosis
Komori, T. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.028 · Cited by 313
Increased Osteoprotegerin Serum Levels in Men with Coronary Artery Disease
Schoppet, M., Sattler, A. M., Schaefer, J. R., Herzum, M., Maisch, B., & Hofbauer, L. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020775 · Cited by 324
Xiong, J., Piemontese, M., Onal, M., Campbell, J., Goellner, J. J., Dusevich, V., Bonewald, L., Manolagas, S. C., & O’Brien, C. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138189 · Cited by 323
Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland
Beleut, M., Rajaram, R. D., Caikovski, M., Ayyanan, A., Germano, D., Choi, Y., Schneider, P., & Brisken, C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915148107 · Cited by 307
“The tumor necrosis family (TNF)member, receptor activator of NF-κB-ligand (RANKL), is important for osteoclast differentiation and lymph-node organogenesis (15) andwas shown to be required for pregnancy-induced lactational mammary gland development (16) and implicated upstream of cyclin D1 in mammary epithelial cells…”
Background
Metadata
- Authors
- Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., & Penninger, J. M.
- Affiliations
- University of Toronto (CA)
- Amgen (United States) (US)
- Corresponding author
- Penninger, Josef M.
- Venue
- Nature
- Published
- 1999-01
- Volume
- 397
- Issue
- 6717
- Pages
- 315-323
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1534645474
- Cited by
- 3,351
- References
- 52
- Citations by year
- 2026: 27 · 2025: 47 · 2024: 58 · 2023: 71 · 2022: 88 · 2021: 114 · 2020: 121 · 2019: 102 · 2018: 95 · 2017: 115 · 2016: 107 · 2015: 125 · 2014: 119 · 2013: 138 · 2012: 162
- FWCI
- 49.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- osteoprotegerin ligand, RANKL, osteoclastogenesis, osteopetrosis, tooth eruption, lymphocyte development, dendritic cells, T cell development, B cell development, osteoblasts
- MeSH terms
- Animals, B-Lymphocytes, Carrier Proteins, Cell Differentiation, Cells, Cultured, Dendritic Cells, Female, Embryonic and Fetal Development, Growth Substances, Hematopoiesis, Extramedullary, Hematopoietic Stem Cells, Lymph Nodes, Lymphocyte Activation, Lymphocytes, Male, Membrane Glycoproteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Molecular Sequence Data, Osteoclasts, Osteogenesis, Osteopetrosis, T-Lymphocytes, Thymus Gland, Cytokines, Mutagenesis, Bone Remodeling, Gene Targeting, Leukopoiesis, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.